-
Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight
15 Oct 2024 23:27 GMT
… -Sensitive Prostate Cancer Treatment Drugs
Related Reports
Metastatic Castration-Sensitive Prostate Cancer Market
Metastatic Castration-Sensitive Prostate Cancer …
-
Why ‘Genetic Testing is Critical’ in Patients with Prostate Cancer
15 Oct 2024 19:04 GMT
… therapies or personalized medicine for patients.”
… the Food and Drug Administration (FDA) has approved … prostate cancer that expresses a BRCA mutation, and Lynparza (olaparib) plus abiraterone … of treatment developments for patients with prostate cancer.
“ …
-
Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain
15 Oct 2024 17:00 GMT
… new prostate cancer treatments, visit @ Prostate Cancer Drugs Table of Contents
1.
Prostate Cancer Pipeline Report Introduction
2.
Prostate Cancer …
-
GU Oncologists Anticipate Earlier Role of Lutetium-177 PSMA-617 in Prostate Cancer
14 Oct 2024 15:54 GMT
… chemotherapy.
In the wake of the approval, improved availability of the drug … -p trial (NCT04419402) from the Australian and New Zealand Urogenital and Prostate Cancer Trials … approved by FDA as first targeted radioligand therapy for treatment of progressive …
-
Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer
12 Oct 2024 11:18 GMT
… prostate cancer. Image: Adobe Stock.
Enzalutamide and abiraterone acetate are common treatments … for men with metastatic castration-resistant prostate cancer … -resistant prostate cancer] treatment strategies,” …
-
Pfizer’s Drug Combo Prolongs Lives in Advanced Prostate Cancer Patients
10 Oct 2024 16:20 GMT
Pharmaceutical giant Pfizer announced on Thursday that a combination of its drugs … the treatment of mCRPC, a type of prostate cancer that … .
In the clinical trial, the Talzenna-Xtandi … Lynparza, alongside hormone therapy abiraterone, to treat mCRPC patients …
-
Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
09 Oct 2024 08:18 GMT
… advanced prostate cancer, regimens combining treatments with … medications for cancer and concomitant disorders.16
Thirdly, potential drug-drug … from Janssen Pharmaceuticals. Dr Adamson … Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. …
-
Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC
17 Oct 2024 21:05 GMT
… 1000 mg of oral abiraterone acetate (Zytiga) … symptomatic skeletal event, chemotherapy or pain progression; … on study treatment. Reasons for treatment discontinuation included … with metastatic castration-resistant prostate cancer (mCRPC): Final overall …
-
Pfizer’s cancer drug combo improves overall survival in late-stage study
10 Oct 2024 11:24 GMT
… advanced prostate cancer in a late-stage study.
The drug combination … treatment.
mCRPC is an advanced stage of the disease where the cancer … Talzenna’s label.
The FDA had also approved AstraZeneca … combination with hormone therapy abiraterone last year to treat …
-
Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs - Daniel Joyce
02 Oct 2024 00:22 GMT
… prostate cancer medication costs on everyone who sees advanced prostate cancer … drug component of Medicare. And they looked at those patients filling abiraterone … treatments that are available in this space, like chemotherapies … , but also doctors. And they get …